Halozyme To Report Third Quarter 2023 Financial and Operating Results

Halozyme Therapeutics, Inc. +3.27% Pre

Halozyme Therapeutics, Inc.

HALO

41.11

41.11

+3.27%

0.00% Pre

SAN DIEGO, Oct. 30, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2023 financial and operating results on Monday, November 6, 2023, following the close of trading.

Halozyme will host a conference call on Monday, November 6, 2023 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://events.q4inc.com/attendee/504047695.

A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com.

About Halozyme

Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. As the innovators of the ENHANZE® technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the delivery of injected drugs and fluids in order to reduce the treatment burden to patients. Having touched more than 700,000 patient lives in post-marketing use in seven commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, AbbVie, Eli Lilly, Bristol Myers Squibb, Alexion, argenx, Horizon Therapeutics, ViiV Healthcare and Chugai Pharmaceutical.

Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The Company has a commercial portfolio of proprietary products including XYOSTED® and TLANDO® and partnered commercial products and ongoing product development programs with several pharmaceutical companies including Teva Pharmaceuticals and Idorsia Pharmaceuticals.

Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility.

For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.

Contacts:

Tram Bui

VP, Investor Relations and Corporate Communications

609-359-3016

tbui@halozyme.com

Dawn Schottlandt

Argot Partners

212-600-1902

Halozyme@argotpartners.com

Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.) (PRNewsfoto/Halozyme Therapeutics, Inc.)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-to-report-third-quarter-2023-financial-and-operating-results-301972021.html

SOURCE Halozyme Therapeutics, Inc.

Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via